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Boston, Massachusetts; Montreal, Quebec, Canada; and Campinas, São Paulo, BrazilOBJECTIVES This study tested whether myocardial extracellular volume (ECV) is increased in pa-
tients with hypertension and atrial ﬁbrillation (AF) undergoing pulmonary vein isolation and whether
there is an association between ECV and post-procedural recurrence of AF.
BACKGROUND Hypertension is associated with myocardial ﬁbrosis, an increase in ECV, and AF. Data
linking these ﬁndings are limited. T1 measurements pre-contrast and post-contrast in a cardiac magnetic
resonance (CMR) study provide a method for quantiﬁcation of ECV.
METHODS Consecutive patients with hypertension and recurrent AF referred for pulmonary vein
isolation underwent a contrast CMR study with measurement of ECV and were followed up prospectively
for a median of 18 months. The endpoint of interest was late recurrence of AF.
RESULTS Patients had elevated left ventricular (LV) volumes, LV mass, left atrial volumes, and
increased ECV (patients with AF, 0.34  0.03; healthy control patients, 0.29  0.03; p < 0.001). There
were positive associations between ECV and left atrial volume (r ¼ 0.46, p < 0.01) and LV mass and a
negative association between ECV and diastolic function (early mitral annular relaxation [E0],
r ¼ 0.55, p < 0.001). In the best overall multivariable model, ECV was the strongest predictor of
the primary outcome of recurrent AF (hazard ratio: 1.29; 95% conﬁdence interval: 1.15 to 1.44;
p < 0.0001) and the secondary composite outcome of recurrent AF, heart failure admission, and death
(hazard ratio: 1.35; 95% conﬁdence interval: 1.21 to 1.51; p < 0.0001). Each 10% increase in ECV was asso-
ciated with a 29% increased risk of recurrent AF.
CONCLUSIONS In patients with AF and hypertension, expansion of ECV is associated with
diastolic function and left atrial remodeling and is a strong independent predictor of recurrent AF
post–pulmonary vein isolation. (J Am Coll Cardiol Img 2014;7:1–11) ª 2014 by the American College
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AF = atrial ﬁbrillation
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
ECG = electrocardiography
ECV = extracellular volume
HR = hazard ratio
HTN = hypertension
LA = left atrial
LGE = late gadolinium
enhancement
LV = left ventricular
PVI = pulmonary vein isola
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2ystemic arterial hypertension (HTN) is one of
the most common risk factors for the devel-
opment of atrial ﬁbrillation (AF) (1). An
early myocardial response in adjustment to
pressure overload in HTN is an increase in the
myocardial extracellular volume (ECV) due to the
development of pathological myocardial ﬁbrosis (2).
Myocardial ﬁbrosis is associated with myocardial
stiffening, diastolic dysfunction, and elevated left
atrial (LA) pressure, which are all key factors
involved in the development of AF. However, there
are limited data directly linking myocardial ﬁbrosisSee page 12with AF (3,4), and data suggest that myocardial
ﬁbrosis in HTN is potentially reversible, especially
at an early stage (5). The gold standard for detectionNeilan has re
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tionof myocardial ﬁbrosis, endomyocardial
biopsy, is invasive. The current optimal
noninvasive test for detection of replace-
ment myocardial ﬁbrosis, such as that
which occurs with a myocardial infarction,
is cardiac magnetic resonance (CMR)
with late gadolinium enhancement (LGE)
(6). However, LGE-CMR depends on
focal contrast enhancement relative to a
normal area of myocardium. Disease pro-
cesses such as HTN are likely diffuse and
lack a normal reference myocardium (7).
Consistent with this are published data on
the presence of LGE in patients with
HTN, ranging from 0% to approximately
50% (8,9), underestimating both the
presence and extent of ﬁbrosis suggestedby pathological data (10–12).
These limitations have prompted research into
novel CMR-based quantitative techniques for
measurement of myocardial ECV. The ECV
derived using a contrast CMR study is derived from
pre-contrast and post-contrast T1 measurements
(13–17), has been validated as a noninvasive esti-
mate of myocardial ﬁbrosis (15,17), and an elevated
ECV is associated with increased mortality (18).
However, there are limited data on whether theceived an American Heart Association Fellow to Faculty Grant (1
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eceived July 31, 2013; accepted August 12, 2013.ECV derived by CMR is abnormal in patients with
HTN (19); furthermore, there are limited data
linking expansion of ECV with adverse clinical
outcomes (18). However, a study testing a broad
group of patients with HTN for both expansion of
ECV and linking expansion of ECV in patients
with isolated HTN to adverse events requires pre-
liminary data. Before pulmonary vein isolation
(PVI), we routinely perform imaging of pulmonary
vein anatomy with CMR, and HTN is one of the
primary etiologies of AF in patients requiring PVI.
Therefore, we tested whether T1 measurements
could detect expansion of ECV in patients with
HTN undergoing PVI for treatment of recurrent
AF, whether the ECV in this population was
associated with other measures of cardiovascular
structure and function, and whether an elevated
ECV in this population was associated with risk of
recurrent AF after PVI.METHODS
Study population. We performed a prospective
observational study of consecutive patients with
HTN undergoing PVI for treatment of recurrent
AF. The cohort underwent CMR that included
gadolinium between July 2009 and January 2012.
Patients were referred for a CMR study speciﬁcally
for imaging of pulmonary veins before PVI for
treatment of recurrent AF. We choose this popu-
lation for 2 reasons: the incidence of isolated HTN
is high among patients with AF, and patients
scheduled to undergo PVI for treatment of AF are
routinely referred for CMR-based imaging of the
pulmonary veins at our institution. To limit the
contribution of other pathologies that expand
myocardial ECV, we excluded patients with dia-
betes mellitus, myocardial infarction (by either
history according to the presence of pathological
Q-waves on electrocardiography [ECG] or a typical
LGE infarct pattern), severe renal failure (glomer-
ular ﬁltration rate <30 ml/m2), a history of heart
failure or any prior documented reduced left ven-
tricular ejection fraction (<50%), signiﬁcant valvular
heart disease (greater than moderate aortic stenosis,2FTF12060588). Dr. Shah has received minor consulting fees
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Figure 1. CMR Study Protocol
In brief, 453 patients underwent CMR before ablation of atrial ﬁbrillation.
We excluded patients who were not in sinus rhythm at the time of the study
and patients who had known alternate contributors to myocardial ﬁbrosis.
CMR ¼ cardiac magnetic resonance; EF ¼ ejection fraction.
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3aortic insufﬁciency, mitral regurgitation, and mitral
stenosis), an inﬁltrative cardiomyopathy by history
or imaging, and patients who were not in sinus
rhythm at the time of the CMR. All patients
meeting the inclusion criteria and without exclusion
criteria participated in the study, including those
who underwent ablation for AF before the study
period or at another institution. HTN and the
presence of left ventricular hypertrophy (LVH) were
deﬁned using published criteria (20,21). For the
active cohort, screening consisted of a comprehensive
questionnaire detailing medical history (including
current medications) and standard anthropometric
data, as well as a clinical evaluation that included
blood pressure, heart rate, serum creatinine level,
hematocrit, ECG, and echocardiography. Healthy
volunteer control patients were recruited by open
enrollment. For healthy control patients we exclu-
ded patients with a history of HTN, known car-
diac disease, renal failure (glomerular ﬁltration rate
<60 ml/m2), or diabetes. Screening for volunteers
similarly consisted of a comprehensive questionnaire
detailing medical and medication history, standard
anthropometric data, and measurement of blood
pressure, heart rate, serum creatinine level, and he-
matocrit. Healthy control patients did not undergo
ECG or echocardiography. Data were entered into a
registry at the time of the CMR study. The protocol
was approved by the Partners Healthcare System
Institutional Review Board.
Standard CMR protocol. All images were acquired
with ECG gating and breath holding with the pa-
tient in a supine position. Subjects underwent im-
aging with a 3.0-TCMR system (TimTrio; Siemens
Medical Systems, Erlangen, Germany). The basic
CMR protocol consisted of cine steady-state free
precession imaging as previously described (22). All
patients underwent an LGE imaging protocol
(repetition time: 4.8 ms; echo time: 1.3 ms; inversion
time: 200 to 300 ms) for focal myocardial ﬁbrosis.
A segmented inversion-recovery pulse sequence for
LGE was used starting 10 to 15 min after a 0.15
mmol/kg single bolus dose of gadolinium DTPA
(Magnevist, Bayer HealthCare Pharmaceuticals
Inc., Wayne, New Jersey).
Myocardial ECV fraction. T1 measurements were
performed with an ECG-gated Look-Locker se-
quence with a non–slice-selective adiabatic inversion
pulse, followed by a gradient-echo acquisition as
previously described (19,22). We have previously
tested and validated this sequence as being inde-
pendent of heart rate in both clinical studies and
with phantom models (23,24). The T1 sequence
was performed in a single slice in the mid-ventricleand was repeated in the same mid left ventricular
(LV) short-axis slice once before and 3 additional
times after the injection of gadolinium, spanning an
approximately 30-min period (Fig. 1). For each
Look-Locker sequence, the endocardial and
epicardial borders of the left ventricle were traced
and divided into 6 standard segments; the segments
were numbered 1 to 6 starting from the anterior
right ventricular insertion point and proceeding
in a clockwise direction (Medis, Leiden, the
Netherlands). The reciprocal of T1 (R1 ¼ 1/T1) was
used to plot the myocardial R1 against the R1 in the
blood pool and calculate the slope by linear regres-
sion, using all measurement points with an R1 of
<3.0 s1 (19). The slope of the linear relationship
(the partition coefﬁcient for gadolinium, lGd) was
calculated, and the ECV for all 6 myocardial seg-
ments was quantiﬁed as reported previously (13,14).
A global ECV for each patient or healthy control
was then calculated by averaging the 6 myocardial
segmental values. Regions with visible LGE were
not excluded from ECV measurements.
Echocardiography. A Vivid 7 ultrasound system
(GE Medical Systems, Milwaukee, Wisconsin) was
used for standard and tissue Doppler echocardiog-
raphy. Pulmonary artery systolic pressure was esti-
mated from the tricuspid regurgitant velocity plus an
estimate of right atrial pressure derived from the
inferior vena cava. Tissue Doppler myocardial ve-
locities were acquired in early diastole (E0) at the
Figure 2. Flow Diagram for Study
In general, 4 to 5 T1 measurements were recorded for each patient in the study. We recorded 1 T1 measurement pre-contrast and 3 to 4
measurements post-contrast. We also completed a magnetic resonance angiogram for pulmonary vein identiﬁcation, a late gadolinium
enhancement sequence, and steady-state free precession imaging of the left ventricle and right ventricle. CMR ¼ cardiac magnetic resonance;
Gd ¼ gadolinium; LGE ¼ late gadolinium enhancement; MRV ¼ magnetic resonance venography.
Table 1. Baseline Ch
Healthy Control Pati
Mean age, yrs
Male
Body mass index, kg/
Heart rate, beats/min
Systolic blood pressur
Diastolic blood pressu
Hematocrit, %
Glomerular ﬁltration r
Values are mean  SD or
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4lateral and septal aspects of the mitral annulus in the
apical 4-chamber view. Measurements for the E0
were averaged from 3 successive heartbeats. The
ratio of the transmitral E wave velocity to the tissue
Doppler E0 was calculated as a measure of LA
pressure.
Clinical follow-up. The primary outcome of interest
was recurrence of AF. The secondary outcome of
interest was a composite of death, admission for
decompensated heart failure, and recurrence of AF.aracteristics in Patients With Hypertension Versus
ents
Patients With
Hypertension
(n [ 145)
Healthy Control
Patients
(n [ 20) p Value
58  12 57  11 0.71
96 (66) 13 (65) 0.99
m2 30  4 28  6 0.07
75  16 69  11 0.12
e, mm Hg 133  10 123  10 0.001
re, mm Hg 81  6 74  8 0.001
40  3 41  4 0.30
ate, ml/m2* 78  21 95  11 0.01
n (%). *Estimated using the Modiﬁcation of Diet in Renal Disease formula.Recurrence of AF was deﬁned as AF occurring >3
months after PVI and conﬁrmed by either ECG or
cardiac monitoring. Patients underwent ECG at all
clinical visits, but routine prolonged cardiac moni-
toring was not performed in the absence of symp-
toms. We ascertained mortality using the Social
Security Death Index and conﬁrmed using elec-
tronic chart review and, if necessary, contact with
the primary providers. Hospital stay with worsening
heart failure was deﬁned as the occurrence of
symptoms consistent with heart failure together
with the absence of recognized AF as a cause and
the need for treatment with diuretic agents (25).
Patients were followed up post-procedure at 3- to
6-month intervals via clinic visits. We contacted
patients who were no longer being followed up in
the clinic by telephone and conﬁrmed data via
correspondence with the patients’ physicians. Pati-
ents without events were censored at the date of the
last available follow-up. Complete follow-up was
obtained for all patients.
Statistical analysis. Continuous data are presented
as mean  SD. Continuous data were compared
using an unpaired Student t test or Mann-Whitney
nonparametric U test as appropriate. Nominal data
are presented as numbers and percentages and were
compared with chi-square test. We determined the
association between ECV and other cohort
Table 2. Clinical, Electrocardiographic, and Echocardiographic
Characteristics in Patients With Hypertension
Clinical variables
Family history of hypertension 26 (18)
Hyperlipidemia 52 (36)
Cigarette smoking (history or active) 14 (10)
Obstructive sleep apnea 25 (17)
Medications
ACE 78 (54)
ARB 37 (26)
Beta-blocker 103 (71)
Thiazide diuretic 59 (41)
Calcium channel blocker 55 (38)
Spironolactone 15 (10)
Alpha-blocker 13 (9)
Other 10 (7)
Coumadin 145 (100)
Aspirin 46 (32)
Statin 51 (35)
Electrocardiography
PR interval, ms 171  28
QRS duration, ms 101  15
QTc duration, ms 437  33
LVH, n (%) 18  12
Echocardiography
LVEF, % 59  7
LVIDd, mm 48  6
Estimated PASP, mm Hg 29  7
LA dimension, mm 41  5
E/A ratio 1.1  0.5
Deceleration time, ms 216  49
e0 medial, cm/s 6.1  1.2
a0 medial, cm/s 7.6  1.6
e0 lateral, cm/s 6.3  1.6
a0 lateral, cm/s 8.0  2.0
E/e0 12.2  5.1
Values are n (%) or mean  SD.
a0 lateral ¼ late lateral mitral annular relaxation velocity; a0 medial ¼ late
medial mitral annular relaxation velocity; ACE ¼ angiotensin-converting
enzyme inhibitor; ARB ¼ angiotensin receptor blocker; e0 lateral ¼ early
lateral mitral annular relaxation velocity; e0 medial ¼ early medial mitral
annular relaxation velocity; E/A ratio ¼ ratio of early transmitral ﬁlling to late
transmitral ﬁlling; E/e0 ¼ ratio of early transmitral ﬁlling to early mitral annular
velocity; LA dimension ¼ left atrial anterior-posterior dimension; LVEF ¼ left
ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; LVIDd ¼ left
ventricular internal dimension in diastole; PASP ¼ pulmonary artery systolic
pressure.
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5characteristics using a Pearson correlation. Multiple
groups were compared using analysis of variance; if
the ﬁndings were signiﬁcant, post-hoc comparison
between groups was performed with Tukey test.The hazard ratio (HR) was calculated for the pri-
mary and secondary outcomes using a Cox regres-
sion model. Considering all the signiﬁcant variables
in the univariable analysis, we sought the best overall
multivariable models for the primary and secondary
endpoints by stepwise forward selection with a
probability to enter set at p < 0.05 and to remove
the effect from the regression at p < 0.05. Event-
free survival was determined according to the
Kaplan-Meier method using the median ECV
value, and comparisons of cumulative event rates
were performed by the log-rank test. We assessed
interobserver and intraobserver variability in a
randomly selected group of 15 subjects. The inter-
observer and intraobserver characteristics of the
myocardial ECV were compared using Bland-
Altman plots and determination of the 95% limits
of agreement between methods. To test whether
there were differences in ECV at the base, mid, and
apex of the left ventricle among patients, a pilot
study of the initial 20 patients enrolled was per-
formed and included T1 measurements at the 3
corresponding slices. Values were compared with
analysis of variance for repeated measures. A 2-
tailed p value <0.05 was deemed signiﬁcant. SAS
version 9.2 was used for statistical analysis (SAS
Institute Inc., Cary, North Carolina).
RESULTS
Between July 2009 and January 2012, 453 patients
with AF were referred for a CMR study for iden-
tiﬁcation of pulmonary vein anatomy before PVI.
Of these patients, 295 (65%) were in sinus rhythm
at the time of the study; 150 were excluded from our
analytic sample on the basis of pre-speciﬁed criteria,
leaving a ﬁnal study cohort of 145 patients who met
the inclusion criteria (Fig. 2). There were 96 men
(66%) with an average age of 58  12 years (range
36 to 85 years). The average body mass index
was 30  4 kg/m2, systolic blood pressure was
133  10 mm Hg, and diastolic blood pressure was
81  6 mm Hg (Table 1). The control group
consisted of 65% men with an average age of 57 
11 years and an average body mass index of 28  6
kg/m2 (Table 1). Overall, 28 patients (19%) had a
prior ablation.
Clinical, ECG, and echocardiographic parameters in
the study group with HTN and recurrent AF. HTN
was diagnosed a median of 52 months before the
CMR study (interquartile range: 28–68months), and
AF was diagnosed a median of 37 months before the
CMR study (interquartile range: 26–62 months).
Eighteen patients (12%) had LVH. On
Table 3. Cardiac Magnetic Resonance Variables
Patients With
Hypertension
(n [ 145)
Healthy
Control Patients
(n [ 20) p Value
LVEDV, ml 155  35 131  27 0.01
LVESV, ml 64  20 46  14 0.001
LVEDV indexed, ml/m2 79  18 68  12 0.009
LVESV indexed, ml/m2 32  10 24  8 0.003
LV mass index, mg/m2 68  20 45  8 <0.001
RVEDV, ml 153  37 154  27 0.009
RVESV, ml 73  23 76  8 0.015
RVEDV indexed, ml/m2 76  16 67  12 0.031
RVESV indexed, ml/m2 36  10 31  7 0.04
Maximal LA volume, ml 118  28 66  15 <0.001
Minimal LA volume, ml 64  18 23  9 <0.001
Maximal LA volume indexed, ml/m2 45  15 36  9 <0.001
Minimal LA volume indexed, ml/m2 25  9 13  5 <0.001
LVEF, % 60 (57–67) 60 (57–66) 0.71
RVEF, % 53  6 54  5 0.53
lGd, partition coefﬁcient 0.56  0.06 0.48  0.05 <0.001
ECV 0.34  0.03 0.28  0.03 <0.001
Values are mean  SD or median (interquartile range).
ECV ¼ extracellular volume fraction; Gd ¼ gadolinium; LA ¼ left atrial; LV ¼ left ventricular; LVEDV ¼ left
ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; maximal LA volume
indexed ¼maximal left atrial volume indexed to body surface area; minimal LA volume indexed ¼minimal
left atrial volume indexed to body surface area; RVEDV ¼ right ventricular end-diastolic volume; RVEF ¼
right ventricular ejection fraction; RVESV ¼ right ventricular end-systolic volume; other abbreviations as in
Table 2.
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6echocardiography, patients had normal LV size and
function, normal estimated pulmonary artery pres-
sure, and normal estimated LA ﬁlling pressure
(Table 2).Figure 3. Bland-Altman Plots
The 95% limits of agreement between (A) 2 observers and (B) for a sing
shown. The mean percentage difference between observers was 5.9%,
intraobserver variability was 4.8%, with an absolute SD of 0.015.CMR parameters. CMR parameters for patients and
healthy control patients are presented in Table 3. In
brief, patients had increased LV, right ventricular,
and LA volumes and LV mass in comparison to
age- and sex-matched healthy volunteers. LGE was
an infrequent ﬁnding and observed in 3 patients. Of
these, 1 patient had mid-myocardial LGE involving
the basal anteroseptal segment, 1 patient had diffuse
LGE involving the mid-inferoseptal segment and
the mid-anteroseptal segment, and 1 patient had
LGE involving the posterior right ventricular
insertion point in the basal slice.
Myocardial ECV. The ECV was increased in pa-
tients (Table 3). The ECV was similar in men and
women (0.33  0.04 vs. 0.34  0.03, respectively;
p ¼ 0.18) and was not different between the 6
segments within the mid-ventricular slice (anterior
segment through anteroseptal segment: 0.34 
0.04, 0.33  0.04, 0.33  0.04, 0.33  0.04, 0.34 
0.04, and 0.34  0.04; p ¼ 0.38 for trend). In a
substudy of the initial 20 patients, we tested the
ECV at the base, mid, and apex of the left ventricle.
The ECV measured 0.34  0.03 at the base, 0.34 
0.03 at the mid-LV slice, and 0.35  0.04 at the
apex of the left ventricle (p ¼ 0.56). We also
measured the interobserver and intraobserver vari-
ability in 15 randomly selected studies. The limits of
agreement were 0.017 to þ 0.015 for interob-
server agreement and 0.015 to þ 0.015 for
intraobserver agreement (Fig. 3). In patients with
HTN, there was a positive association between the
ECV and indexed LA volume (r ¼ 0.46, p < 0.01)
and LV mass index (r ¼ 0.45, p < 0.01) and ale observer for 15 randomly selected patients with hypertension are
with an SD of the absolute difference of 0.02. The mean percentage
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7negative association between the ECV and early
mitral annular relaxation (E0, r ¼ 0.55, p <
0.001).
Clinical follow-up. Patients were followed up for a
median of 18 months. During the follow-up
period, there were 45 episodes of recurrent AF.
For the composite outcome of death, heart failure
admission, and AF, there were 52 events (2
deaths, 5 heart failure admissions, and 45 late
recurrences of AF). On univariate analysis to test
the association between variables and the recur-
rence of AF, presence of sleep apnea (HR: 1.89,
95% CI: 1.01 to 3.74; chi-square: 3.97; p ¼
0.04), LV mass index (HR: 1.02; 95% CI: 1.00
to 1.03; chi-square: 4.36; p ¼ 0.04), indexed LA
volume (HR: 1.03; 95% CI: 1.00 to 1.06; chi-
square: 4.74; p ¼ 0.03), and ECV (HR: 1.30;
95% CI: 1.16 to 1.46; chi-square: 20.0; p <
0.0001) were associated with the recurrence of
AF (Table 4). In the best overall multivariable
model, ECV was the only variable selected for
association with recurrent AF (HR: 1.29; 95%
CI: 1.15 to 1.44; chi-square: 18.8; p < 0.0001).
Kaplan-Meier curves were generated for com-
parison of event-free survival from recurrent AF
according to the median ECV of 0.34 (Fig. 4).
Data from the secondary outcome analysis are
presented in Online Tables 1 and 2 and Online
Figures 1 and 2. In an analysis extending the
outcome of interest to include death and heart
failure admissions, the presence of sleep apnea,
LV mass index, LA volume, and ECV provided
the strongest association with the combined
outcome. In a multivariable model, the presence
of sleep apnea and ECV remained signiﬁcantly
associated with the composite outcome (Online
Table 2). For the secondary outcome of death,
heart failure admission, and recurrence of AF,
each 10% increase in ECV was associated with a
24% increase in the risk of the combined
endpoint. Kaplan-Meier curves were generated
for the comparison of event-free survival from the
composite outcome according to the median
ECV of 0.34 (Online Fig. 2).
D I SCUSS ION
In this study, we assessed the prognostic impact of
ECV on the recurrence of AF in a cohort of pa-
tients with HTN undergoing PVI for management
of their arrhythmia. The major ﬁnding of this
study was that the ECV was the strongest pre-dictor in the best overall model for recurrent AF
post-PVI. This prognostic ﬁnding was supported
by several potential mechanistic observations;
expansion of ECV was associated with an
increased LV mass, increased LA volume, and
reduced diastolic function. These data provide
imaging evidence of an association between
expansion of the ECV, altered myocardial func-
tion, elevated LA volume, and adverse cardiovas-
cular outcomes.
There are extensive data suggesting a strong
interplay between diastolic function, LA size, and
the occurrence of AF (26,27). Expansion of the
myocardial ECV due to myocardial ﬁbrosis is one of
the key intermediate steps in the development of
diastolic dysfunction (10,28). Using T1 measure-
ments, we measured the HTN-associated expansion
of ECV and found an association between ECV,
diastolic function, and LA size, suggesting a
mechanistic link between HTN, myocardial ﬁbrosis,
diastolic function, atrial remodeling, and recurrence
of AF. The increase in ECV is likely due to a
combination of HTN and AF because there are data
supporting both as a cause of expansion of ECV
(10,29,30). However, there are limited pathological
and imaging data providing a link between expan-
sion of ECV and AF (3,4,31), between ECV and
HTN (19), and testing the association between
ECV and adverse outcomes. Swartz et al. (31)
demonstrated a link between serum measures of
collagen turnover, atrial ﬁbrosis, and the occurrence
of AF. Also, in a broad cohort of patients referred
for CMR study before PVI, Ling et al. (4) showed
an association between T1 measures post-contrast
with both age and persistent AF. Our data pro-
vide support and extend these ﬁndings. There are
also important differences that merit some discus-
sion. We speciﬁcally looked at patients with isolated
HTN and not all patients with AF and found in
patients with HTN that the ECV was associated
with LV mass, diastolic function, and LA size. We
also found clinically important consequences of the
ECV measurement; ECV was the strongest inde-
pendent predictor of recurrent AF in a relatively
homogeneous population. These data suggest an
association between HTN, myocardial ﬁbrosis,
diastolic function, adverse LA remodeling, and
recurrent AF.
We studied patients with recurrent AF with
HTN who were referred for PVI. We did not
study patients with isolated asymptomatic HTN.
However, in broad groups of patients with HTN,
Table 4. Univariate Analyses for Association With Recurrence of Atrial Fibrillation
HR 95% CI Chi-Square p Value
Age 1.02 0.99–1.03 3.01 0.10
Male 0.81 0.44–1.49 0.45 0.65
Duration of hypertension 1.00 0.99–1.01 1.02 0.31
Duration of atrial ﬁbrillation 1.00 0.99–1.01 0.06 0.80
Cigarette smoking 0.99 0.35–2.73 0.01 0.97
Sleep apnea 1.89 1.01–3.74 3.97 0.04
Prior pulmonary vein isolation 1.21 0.72–2.17 1.56 0.23
Hyperthyroidism 0.82 0.19–3.38 0.08 0.78
Excess alcohol intake 0.79 0.25–2.58 0.14 0.70
Family history of hypertension 1.02 0.48–2.19 0.01 0.95
Hyperlipidemia 0.79 0.42–1.46 0.56 0.45
Medications
Thiazide diuretic 1.04 0.57–1.88 0.01 0.91
Loop diuretic 1.12 0.35–3.62 0.04 0.85
ACE 0.94 0.52–1.69 0.04 0.84
ARB 0.82 0.41–1.65 0.31 0.58
Beta-blocker 1.11 0.57–2.14 0.09 0.76
Calcium channel blocker 0.65 0.34–1.25 1.66 0.20
Aspirin 1.01 0.54–1.90 0.01 0.97
Class 1/class 3 antiarrhythmic 1.32 0.66–2.68 0.61 0.43
Statin therapy 0.87 0.42–1.60 0.21 0.65
Inhibition of aldosterone receptor 1.03 0.43–2.44 0.01 0.94
Alpha-blocker 0.53 0.13–2.17 0.79 0.34
Digoxin 0.95 0.13–6.92 0.01 0.96
Body mass index 1.01 0.95–1.08 0.18 0.67
Systolic blood pressure 0.99 0.98–1.01 0.76 0.38
Diastolic blood pressure 1.01 0.98–1.04 0.72 0.40
Heart rate 1.00 0.98–1.02 0.08 0.77
Glomerular ﬁltration rate 0.97 0.93–1.03 2.10 0.15
Hematocrit 1.01 0.99–1.01 0.05 0.86
Electrocardiographic parameters
PR interval 1.00 0.99–1.01 0.53 0.46
QRS interval 1.01 0.99–1.03 0.71 0.40
QTc interval 1.00 0.99–1.01 0.11 0.74
LVH 1.33 0.66–2.02 1.23 0.26
Continued on the next page
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8LVH or an increase in LV mass is a maladaptive
response phenotype to chronic pressure overload
observed in selected patients. Patients display a
range of markedly different cardiac phenotype re-
sponses to HTN, and it is clear that the presence
of this abnormal cardiac phenotype marks a group
with HTN at signiﬁcantly increased risk for
adverse outcomes (32–34). Targeted therapy onthe basis of either the presence of LVH or
increased LVH mass has prognostic signiﬁcance
(32). An increase in LV mass or LVH in patients
with HTN is the macroscopic representation of a
combination of increased cardiac size, increased
cell size, and myocardial ﬁbrosis (35). Some of the
current standard methods for assessment of the
cardiac adaptation to HTN include measurement
of cardiac size. Methods for measurement of car-
diac size are limited by a combination of poor
sensitivity (21), acoustic windows (36), geometric
assumptions (37), criteria for normalization (38),
and the deﬁnitions of normal (39). Indeed, in this
study, only 12% of patients had LVH on the basis
of ECG criteria and only 24 patients (17%) had
LVH as determined using published CMR criteria
(40). These data suggest that a more accurate
method of examining tissue phenotypes in
response to stressors such as HTN may be of
beneﬁt for stratifying risk. In this study, the ECV
predicted a far stronger risk of recurrence of AF, or
a combination of death, heart failure admission, or
recurrence of AF, than the presence of LVH on
ECG, CMR-derived LV mass, or indeed mea-
surement of diastolic function or LA volume.
These data suggest that more accurate tissue
characterization of response of patients with HTN
may be beneﬁcial and warrants further investiga-
tion. We believe that this measurement may
represent an extension of current methods in
assessment of patients with pressure overload, and
an extension of this hypothesis may be to measure
ECV in patients with HTN with normal LV mass,
normal LA volume, and normal measures of car-
diac function.
Data on the presence of LGE in patients with
HTN show a wide incidence (0% to 50%) (8,9),
underestimating both the presence and extent of
ﬁbrosis suggested by pathological data (10–12).
The ECV derived by CMR is on the basis of the
serial measurement of myocardial T1 pre-contrast
and post-contrast (13–16,18,41,42), has been
validated against histology (15,17), and is a marker
of adverse outcomes among a broad group of pa-
tients (18). In the healthy state, between 25% and
33% of the normal myocardium consists of the 3-
dimensional extracellular space (2,43) and closely
aligns with the normal value reported in this study.
Here, we provide additive data in a homogeneous
cohort of patients with HTN. In patients with
HTN, there was an association between ECV,
diastolic function, and LA size. These data are
consistent with work in other populations in which
an association between T1 values and markers or
Table 4. Continued
HR 95% CI Chi-Square p Value
Echocardiographic parameters
LVEF 0.98 0.94–1.02 0.28 1.17
LVIDd 1.01 0.96–1.06 0.16 0.68
Estimated PASP 1.05 1.00–1.10 3.76 0.05
Transmitral E velocity 1.00 0.98–1.02 0.01 0.97
Transmitral A velocity 1.00 0.99–1.02 0.26 0.61
E/A ratio 1.03 0.49–2.18 0.01 0.93
Deceleration time 1.00 0.99–1.01 0.28 0.60
e0 lateral 0.85 0.69–1.05 2.29 0.13
e0 medial 0.82 0.71–1.03 2.51 0.09
E/e0 1.04 0.99–1.08 2.45 0.10
Cardiac magnetic resonance
LVEDV 1.00 0.99–1.01 0.38 0.53
LVESV 1.00 0.99–1.02 0.83 0.36
LVEF 1.00 0.96–1.05 0.02 0.87
LV mass index 1.02 1.00–1.03 4.36 0.04
RVEDV 1.00 0.99–1.01 0.27 0.60
RVESV 1.00 0.99–1.02 0.08 0.78
RVEF 1.01 0.96–1.07 0.29 0.59
Maximal LA volume indexed 1.05 0.99–1.08 3.71 0.05
Minimal LA volume indexed 1.03 1.00–1.06 4.74 0.03
Partition coefﬁcient for gadolinium, lGd 1.25 1.13–1.37 17.0 <0.0001
Extracellular volume fraction 1.30 1.16–1.46 20.0 <0.0001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 2 and 3.
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9measures of diastolic function has been shown in
patients with heart failure (17), diabetes (44), and
aortic stenosis (45). Ultimately, data provided by
quantiﬁcation of myocardial ECV could have
therapeutic implications. Data on pharmacological
interventions to reduce AF via targeting myocardial
ﬁbrosis have yielded conﬂicting results (46,47),
suggesting that identiﬁcation of a high-risk group
with more extensive ECV expansion may be of
beneﬁt.
Study limitations. This study has to be interpreted
within the context of the design format. We did not
study a broad group of patients with isolated
asymptomatic HTN; we looked speciﬁcally at a
population of patients with recurrent AF and HTN
who were referred for PVI. Although pathological
validation for ECV as a surrogate for myocardial
ﬁbrosis has been reported (15,17), we did not
perform endomyocardial biopsies in our population
to verify the presence of myocardial ﬁbrosis and
correlate the extent of pathological ﬁbrosis with
ECV. We also did not perform serial prolonged
monitoring for recurrence of AF; conﬁrmation of
recurrence was on the basis of the patients’ symp-
toms and likely underestimates the true incidence.
We did attempt to remove known modiﬁers of
ECV such as diabetes, coronary disease, reduced
ejection fraction, and valvular disease; however, the
inclusion of unknown modiﬁers of ECV cannot be
excluded.
CONCLUS IONS
CMR-derived ECV is elevated in patients with
HTN and recurrent AF requiring PVI, is associated
with other adverse structural and functional conse-
quences, and is a strong independent predictor of
adverse cardiovascular outcomes. These data may
support further investigation into whether inter-
vention on the basis of ECV can improve
outcomes.
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